APGE
NASDAQApogee Therapeutics Inc.
News25/Ratings12
News · 26 weeks85+15%
2025-12-282026-06-21
Mix4790d
- SEC Filings18(38%)
- Insider17(36%)
- Other6(13%)
- Earnings3(6%)
- Offering2(4%)
- Analyst1(2%)
Latest news
25 items- SECSEC Form DEFA14A filed by Apogee Therapeutics Inc.DEFA14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form 144 filed by Apogee Therapeutics Inc.144 - Apogee Therapeutics, Inc. (0001974640) (Subject)
- SECSEC Form DEFA14A filed by Apogee Therapeutics Inc.DEFA14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECApogee Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form 8-K filed by Apogee Therapeutics Inc.8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
- PRAbbVie to Acquire Apogee Therapeutics, Deepening Immunology PortfolioProposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseasesApogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitisApogee's pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), is being developed in asthmaApogee shareholders to receive $135.11 per share in cash, for a total equity value of approximately $10.9 billionAbbVie
- INSIDERChief Executive Officer Henderson Michael Thomas sold $1,667,622 worth of shares (20,000 units at $83.38) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,095,987 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECApogee Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
- INSIDERSEC Form 4 filed by Director Fairmount Funds Management Llc4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Director Shah Nimish P4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Director Mckenna Mark C.4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Director Jones William A Jr4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Director Fox Jennifer A.4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Director Bollinger Lisa4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERChief Medical Officer Dambkowski Carl exercised 4,125 shares at a strike of $22.86 and sold $432,905 worth of shares (5,500 units at $78.71) as part of a pre-agreed trading plan, decreasing direct ownership by 0.66% to 205,648 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- PRApogee Therapeutics to Participate in Upcoming June ConferencesSAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), today announced that members of management will participate at the following investor conferences. Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026Fireside Time: 11:40 a.m. ET Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Wednesday, June 10, 2026Fireside Time: 9:20 a.m. ET A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About ApogeeApogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentia
- SECApogee Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECApogee Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
- PRApogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of ZumilokibartUp to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt Combined with company's current total cash of $1.3 billion, this transaction positions Apogee to achieve a self-sustainable financial profile through commercialization of zumilokibart without need for future equity financing Apogee to host webcast with the APEX Phase 2 Part B results today at 8:00 a.m. Eastern Time SAN FRANCISCO and BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class pr
- PRApogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic DermatitisAPEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026 Zumilokibart was well tolerated with a safety profile consistent with other agents in class Strategic financing collaboration with Blackstone Life Sciences announced today expected to provide funding through commercialization of zumilokibart in AD, asthma, and EoE Results support pipeline-in-a-product potential for zumilokibart with asthma and eosinophilic esophagitis (EoE) trial plans shared today Management to host conference call today at 8:00 a.m. ET SAN FRANCISCO and BOSTON, May
- PRApogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on Wednesday, May 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Apogee Therapeutics' live webcast of the Phase 2 APEX Part B results will begin on Wednesday, May 27 at 8:00 a.m. ET. The live webcast can be accessed via this l
- INSIDERChief Executive Officer Henderson Michael Thomas sold $1,641,711 worth of shares (20,000 units at $82.09) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,115,987 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECSEC Form 144 filed by Apogee Therapeutics Inc.144 - Apogee Therapeutics, Inc. (0001974640) (Subject)
- SECSEC Form 10-Q filed by Apogee Therapeutics Inc.10-Q - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECApogee Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
APGE FAQ
6 questionsWhere does APGE stock trade?
Apogee Therapeutics Inc. (APGE) is listed on NASDAQ.What sector and industry is APGE in?
Apogee Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Apogee Therapeutics Inc. go public?
Apogee Therapeutics Inc. (APGE) completed its IPO in 2023.What are analysts saying about APGE?
Apogee Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Rothschild & Co Redburn: Buy on 2026-05-01.What companies are similar to APGE?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare APGE side-by-side with any of them on Quantisnow.How can I track APGE on Quantisnow?
Quantisnow aggregates Apogee Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APGE to receive live email and push alerts on every new disclosure.